Cargando…
A methodological review of national and transnational pharmaceutical budget impact analysis guidelines for new drug submissions
INTRODUCTION: Budget impact analysis (BIA) in health care, sometimes referred to as resource impact, is the financial change in the use of health resources associated with adding a new drug to a formulary or the adoption of a new health technology. Several national and transnational organizations wo...
Autores principales: | Foroutan, Naghmeh, Tarride, Jean-Eric, Xie, Feng, Levine, Mitchell |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6263295/ https://www.ncbi.nlm.nih.gov/pubmed/30538513 http://dx.doi.org/10.2147/CEOR.S178825 |
Ejemplares similares
-
A Comparison of Pharmaceutical Budget Impact Analysis (BIA) Recommendations Amongst the Canadian Patented Medicine Prices Review Board (PMPRB), Public and Private Payers
por: Foroutan, Naghmeh, et al.
Publicado: (2019) -
“Budget Impact Analyses”: A Practical Policy Making Tool for Drug Reimbursement Decisions
por: Jamshidi, Hamid Reza, et al.
Publicado: (2014) -
Transnational corporations in the pharmaceutical industry of developing countries.
Publicado: (1984) -
National Methodological Guidelines to Conduct Budget Impact Analysis for Health Technology Assessment in India
por: Prinja, Shankar, et al.
Publicado: (2021) -
Transnational pharmacogovernance: emergent patterns in the jazz of pharmaceutical policy convergence
por: Wiktorowicz, Mary, et al.
Publicado: (2018)